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The most common seizure disorder in children, febrile
seizures (FS), occurs in 1–10% of children [1]. Although
the pathogenesis of FS remains unclear, many studies
have revealed that genetic components play an impor-
tant role. In 1986, neuropeptide Y (NPY) was found to
be widely distributed throughout the central nervous
system, including the hippocampus, and was shown
to prevent the occurrence of seizures [2]. Woldbye et al
observed that NPY administered through the lateral
ventricle of rats is a powerful inhibitor of motor
seizures as well as electroencephalographic (EEG)
seizures induced by kainic acid [3]. Dube et al also
found that endogenous neuropeptide Y prevents the
recurrence of experimental febrile seizures by increas-
ing the seizure threshold [4]. NPY receptor knockout
mice were found to be more sensitive to kainic acid-
induced seizures [5], suggesting that NPY is critical
for the modulation of the excessive synaptic excita-
tion associated with an epileptic seizure. In addition,
NPY-deficient mice are susceptible to limbic seizures
[6,7]. In a study of patients with alcohol withdrawal
syndrome, Okubo and Harada found that seizures
occurred more frequently in patients with the single
nucleotide polymorphism (SNP) of NPY (nucleotide
5671 C/T) (GenBank Accession no. NW 923240.1) [8].
Based on the above findings, it is reasonable to
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Neuropeptide Y (NPY) has been shown to depress the hyperexcitability of neurons. In the present
study, we investigated the association between the nucleotide (nt) 5671 C/T polymorphism of the
NPY gene and the plasma NPY level in patients with febrile seizures (FS). Fifty-six patients with
FS and 55 control subjects were enrolled. Genotype and allele frequencies were compared. The
frequencies of genotypes TT, TC and CC for the NPY gene nt 5671 C/T polymorphism were 21.4%,
28.6% and 50.0%, respectively, in patients with FS, and 14.6%, 40.0% and 45.4%, respectively, in
control subjects. The frequencies of alleles T and C were 35.7% and 64.3%, respectively, in patients
with FS, while those in the control group were 34.5% and 65.5%, respectively. We found no signifi-
cant relationship between the NPY gene nt 5671 C/T polymorphism and FS. The plasma NPY
concentrations of the FS group, the age-matched non-FS group, and subjects aged > 6 years in the
non-FS group were 48.23 ± 32.49, 55.36 ± 23.12, and 70.10 ± 60.31 pg/mL, respectively. These results
indicate no statistical difference in plasma NPY concentration between FS patients and the non-FS
group. However, plasma NPY concentration was found to increase significantly with age.
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hypothesize that NPY is responsible for the patho-
genesis of FS. To determine whether NPY is associ-
ated with FS pathogenesis, the frequency of this NPY
genetic polymorphism and the plasma concentrations
of NPY were determined in children with FS, and the
possible role of NPY was evaluated.
MATERIALS AND METHODS
This study enrolled 56 Taiwanese patients who had
been clinically diagnosed with FS. All patients met the
stringent criteria for FS described by Freeman [9]. FS
were further classified as typical or atypical. Atypical
FS were defined as seizures that persist for more than
15 minutes, are repeated within the same febrile illness,
or are focal. Each participant (or a responsible adult
in the case of minor children) signed the informed
consent form as approved by the institutional review
board of Kaohsiung Municipal Hsiao-Kang Hospital.
Fifty-five healthy, unrelated, randomly selected indi-
viduals above 6 years of age, without any history of
FS, were recruited as controls for the genetic poly-
morphism study.
Genomic DNA was extracted from peripheral
blood leukocytes using a DNA extraction kit (Gentra
Systems Inc., Minneapolis, MN, USA), and part of
exon 3 of the NPY gene was amplified and sequenced.
DNA amplification was performed in a 50-µL poly-
merase chain reaction (PCR) solution containing 50 ng
of genomic DNA, 200 µM of each dNTP, 2.0 units of
Taq DNA polymerase, 0.3 µM of each primer and
10% DMSO, using a thermal cycler (Hybaid PxE2.0,
Midland, ON, Canada). The sequences of the primers
used to amplify the NPY exon 3 were: forward
primer, 5-ATGCTTCATACACCTAGCTTGC-3; re-
verse primer, 5-TCCTCTGCCTGCTTCTTCA-3. The
PCR conditions were as follows: 94°C for 4 minutes
followed by 35 cycles at 94°C for 30 seconds, 60°C
for 30 seconds and 72°C for 30 seconds, then 72°C for
10 minutes, and storage at 4°C. Amplification prod-
ucts were purified using a Multiscreen filter plate
(Millipore, Billerica, MA, USA) and sequenced on an
ABI 3730 DNA Analyzer (Applied Biosystems, Foster
City, CA, USA).
The concentration of NPY was determined in
some individuals with FS and in the age-matched con-
trol group using an enzyme immunoassay (EIA) kit
(Phoenix Pharmaceuticals Inc., Belmont, CA, USA).
In brief, 50 µL of standard or sample was mixed with
25 µL of primary antiserum and 25 µL of biotinylated
peptide in each well, and then incubated at room tem-
perature for 2 hours. Streptavidin-horseradish perox-
idase (SA-HRP) solution (100 µL/well) was added to
each well after the immunoplate had been washed five
times with 300 µL of assay buffer per well. The immu-
noplate was incubated at room temperature for 1 hour
and then washed six times with 300 µL of assay buffer
per well. TMB substrate solution (100 µL) was added
to each well, and incubation was continued at room
temperature for 1 hour. Reactions were terminated
by adding 100 µL of 2N HCl to each well. Absorbance
(optical density) at 450 nm was determined and these
data were used for statistical analysis.
The significance of the differences in genotype and
allele frequencies between the FS patients and control
subjects was calculated using the χ2 test and logistic
regression. The concentrations of NPY are shown as
mean±standard deviation. All statistical analyses were
performed using SPSS version 12.0 (SPSS Inc., Chicago,
IL, USA). Two-sample t tests were used to compare
the means of the two groups. A value of p < 0.05 was
considered to be statistically significant.
RESULTS
Fifty of the 56 FS patients were placed in the typical
FS group, and the remaining six (10.7%) in the atypi-
cal FS group. Eighteen patients (32.1%) had a positive
family history of FS. The female-to-male ratio was 1 to
1.33 (Table 1). Seventeen of the 56 FS patients (30.3%)
had had two or more FS attacks by the time of our
study. The genotype and allele frequencies of the NPY
Table 1. Demographic data of febrile seizure (FS) and control groups
Typical FS (n = 50) Atypical FS (n = 6) Control (n = 55)
Age (mo) 23.96 ± 11.28 22.67 ± 12.54 174.62 ± 116.29
Sex (M/F) 28/22 4/2 24/31
Family history of FS 17 1 0
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gene nt 5671 C/T polymorphism in each group are
shown in Table 2. The frequencies of TT, TC and CC
genotypes were 21.4%, 28.6% and 50.0%, respectively,
in patients with FS, and 14.6%, 40.0% and 45.4%, re-
spectively, in control subjects. There was no significant
difference between the two groups. The frequencies
of alleles T and C were also not significantly different
between the two groups (35.7% and 64.3%, respec-
tively, in patients with FS vs. 34.5% and 65.5%, re-
spectively, in control subjects). We further divided
the FS patients into two groups (one with a positive
and one with a negative family history of FS) and
then compared the genotypes and allele frequencies
of the two groups. The between-group differences in
genotype or allele frequencies were still insignificant
(Table 3).
The NPY concentrations in the FS, atypical FS, age-
matched non-FS, and non-FS (> 6 years) groups were
48.23 ± 32.49, 33.24 ± 0.47, 55.36 ± 23.12, and 70.10 ±
60.31 pg/mL, respectively (Table 4). The concentration
of NPY was slightly (but not significantly) higher in the
age-matched non-FS group than the FS group. How-
ever, the difference in NPY concentration between the
age-matched non-FS group and the age > 6 years non-
FS group was significant, suggesting a possible age-
dependence pattern (Figure). In addition, the plasma
NPY concentration was lower in patients with atypi-
cal FS than in those with typical FS, highlighting the
Table 2. Genotype and allele frequencies at the nt 5671 C/T site of the NPY gene in febrile seizure (FS) and control groups
FS patients Control subjects p OR 95% CI
TT genotype (%) 12 (21.4) 8 (14.6) 0.583 1.34 0.48, 3.92
TC genotype (%) 16 (28.6) 22 (40.0) 0.313 0.65 0.28, 1.50
CC genotype (%) 28 (50.0) 25 (45.4) 1.00
TT genotype (%) 12 (21.4) 8 (14.6) 0.348 1.60 0.61, 4.44
CC/TC genotype (%) 44 (78.8) 47 (85.4) 1.00
CC genotype (%) 28 (50.0) 25 (45.4) 0.632 1.20 0.56, 2.54
TC/TT genotype (%) 28 (50.0) 30 (54.6) 1.00
T allele (%) 40 (35.7) 38 (34.5) 0.855 1.05 0.61, 1.83
C allele (%) 72 (64.3) 72 (65.6) 1.00
OR = odds ratio; CI = confidence interval.
Table 3. Genotype and allele frequencies at the nt 5671 C/T site of the NPY gene in febrile seizure (FS) patients with
and without family history
Family history
Yes No
p OR 95% CI
TT genotype (%) 3 (16.7) 9 (23.7) 0.652 0.70 0.13, 3.06
TC genotype (%) 6 (33.3) 10 (26.3) 0.719 1.27 0.34, 4.59
CC genotype (%) 9 (50.0) 19 (50.0) 1.00
T allele (%) 12 (33.3) 28 (36.8) 0.718 0.86 0.36, 1.95
C allele (%) 24 (66.7) 48 (63.2) 1.00
OR = odds ratio; CI = confidence interval.
Table 4. Concentration of neuropeptide Y in different groups
FS (n = 10)
Non-FS
Atypical FS (n = 2)
Age ≤ 6 yr (n = 9) Age > 6 yr (n = 19)
Age (mo) 29.60 ± 18.83 29.56 ± 15.55 232.21 ± 131.86 32.50 ± 6.36
NPY (pg/mL) 48.23 ± 32.49 55.36 ± 23.12 70.10 ± 60.31* 33.24 ± 0.47
*Plasma concentration of NPY was significantly higher in individuals aged > 6 years than in individuals aged ≤ 6 years in the non-FS
group, p = 0.036. FS = febrile seizures.
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possible role of NPY in atypical FS. Positive family
history did not significantly influence plasma NPY
concentration in this study (data not shown).
DISCUSSION
Many polymorphisms have been studied in Taiwanese
patients with FS, including polymorphisms in genes
for voltage-gated sodium channel subunits (SCN1A),
brain-derived neurotrophic factor (BDNF), interleukin-
4, α4-subunit of the neuronal nicotinic acetylcholine
receptor (CHRNA4), nicotinic receptor β2 subunit
(CHRNB2), and voltage-gated potassium channel
KCNQ2 [10–15]. However, only the CHRNA4 gene
has been associated with FS. As we already noted, the
relationship between the NPY gene and FS has not
been investigated.
Several biochemical and electrophysiologic find-
ings in experimental models and in tissue from human
epilepsy sufferers have suggested that NPY plays an
important role in suppressing seizures. Lack of inhibi-
tory control by NPY could, therefore, play a role in
epileptogenesis [16,17]. In an animal study, agonists of
the Y1, Y2 and Y5 receptors for NPY were observed to
reduce seizure-like activity in hippocampal cultures
[18]. In contrast, the hyperexcitability of NPY knockout
mice was markedly increased when challenged with
a convulsing agent such as pentetrazole, and the rate
of developing motor convulsions was increased from
30% to 80% [19]. A study of specimens from patients
with mesial temporal lobe epilepsy found that NPY
may mediate inhibition of glutamate release through
upregulation of NPY Y2 receptors [20]. It was also
reported that the expression level of the NPY gene
has a tendency to increase with age [21]. Accordingly,
it is reasonable to expect that the NPY gene might
play a role in the pathogenesis of FS. In our study of
Taiwanese subjects with FS, we found no significant
difference in the genotype and the allele frequencies
of the NPY nt 5671 C/T polymorphism between our
FS and non-FS groups. This finding indicates that FS
has no apparent association with the nt 5671 site of
the NPY gene.
In this study, the plasma NPY concentrations in the
FS group and non-FS age-matched control group were
not significantly different. However, the plasma NPY
concentration was significantly higher in the non-FS
age > 6 years group than the age-matched non-FS
group. Our results suggest the importance of an age-
related increase in plasma NPY concentration in the
physiologic regulation of some neuronal functions,
and the need for further study of its preventive role
in recurrent FS. According to our case-limited data, the
plasma NPY concentration is lower in patients with
atypical FS than in those with typical FS. Whether this
lower concentration indicates that patients lacking
NPY are more susceptible to long-lasting seizures or
recurrent FS would be worthwhile investigating.
In conclusion, we found that plasma concentration
of NPY in patients with no previous FS was signifi-
cantly higher in individuals older than 6 years than
in their age-matched counterparts. In addition, NPY
concentration was found to depend on age. However,
further investigation is needed to determine more
precisely the relationship between this gene and FS.
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